Press release
Biosimilar Insulin Market Access
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba.
More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations.
As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers’ formularies and contracts.
For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/biosimilar-insulin-market-access
Key Topics Covered in this Research Report
US
• Insights and strategic recommendations
• US payers are adopting a wait-and-see approach for biosimilar Basaglar
• Bibliography
FIVE MAJOR EU MARKETS
• Insights and strategic recommendations
• Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
• Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to reduce costs
• Payers use biosimilars to pressure originators on pricing
• Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
• Patient switching requires significant discounts of at least 30%
• Given attractive discounts, payers will use a variety of market access tools to drive Basaglar’s uptake
• Bibliography
To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=35949
About ReportsWorldwide.com
ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.
Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Insulin Market Access here
News-ID: 726942 • Views: …
More Releases from ReportsWorldwide
World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence…
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports.
Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors.
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that…
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports.
This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers:
• CommScope/Airvana
• Comba Telecom
• Ericsson
• Huawei Technologies
• Nokia
• SpiderCloud
• ZTE Corporation
This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021.
To view a detailed description and Table of…
More Releases for Basaglar
US Antidiabetics Drug Market Outlook 2022 Report
“US Antidiabetics Drug Market Outlook 2022” report highlights:
* US Diabetes Epidemiology
* US Antidiabetics Market Overview
* Key Marketed Antidiabetic Drugs in US
* US Biosimilar Insulin Market
* US Antidiabetics Drug Market Future Prospects
Download Report Sample Weblink:
https://www.kuickresearch.com/report-us-antidiabetics-drug-market-outlook-2022.php
For Report Sample Contact: neeraj@kuickresearch.com
Table of Contents
Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics
Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
…
Biosimilar Insulin Market Access
Boston, MA
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer…
Download Sample US Antidiabetics Drug Market Outlook 2022
“US Antidiabetics Drug Market Outlook 2022” report highlights:
US Diabetes Epidemiology
US Antidiabetics Market Overview
Key Marketed Antidiabetic Drugs in US
US Biosimilar Insulin Market
US Antidiabetics Drug Market Future Prospects
For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink:https://www.kuickresearch.com/report-us-antidiabetics-drug-market-outlook-2022.php
Table of Contents
Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics
Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic…
In Depth Research on US Antidiabetics Drug Market Outlook 2022
“US Antidiabetics Drug Market Outlook 2022” report highlights:
* US Diabetes Epidemiology
* US Antidiabetics Market Overview
* Key Marketed Antidiabetic Drugs in US
* US Biosimilar Insulin Market
* US Antidiabetics Drug Market Future Prospects
For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink:https://www.kuickresearch.com/report-us-antidiabetics-drug-market-outlook-2022.php
Table of contents
Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics
Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
2.2 Historical…
US Anti-diabetics Drug Market and Ongoing Outlook 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics
Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic Medication
Treatments Available for Diabetes Mellitus
3.1 Non-Pharmacological Approaches for Diabetes Mellitus
3.2 Pharmacological Approaches for Diabetes Mellitus
Cataloguing of Antidiabetic Agents
4.1…
US Antidiabetics Drug Market US Antidiabetics Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics
Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic Medication
Treatments Available for Diabetes Mellitus
3.1 Non-Pharmacological Approaches for Diabetes Mellitus
3.2 Pharmacological Approaches for Diabetes Mellitus
Cataloguing of Antidiabetic Agents
4.1…
